Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHHE | ISIN: US65343E1082 | Ticker-Symbol: 2US
Tradegate
31.03.25
16:10 Uhr
0,462 Euro
+0,010
+2,10 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXTCURE INC Chart 1 Jahr
5-Tage-Chart
NEXTCURE INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,4390,45721:57
0,4390,45721:58

Aktuelle News zur NEXTCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.H.C. Wainwright maintains Buy rating, $3 target on NextCure stock5
06.03.NextCure GAAP EPS of -$1.993
NEXTCURE Aktie jetzt für 0€ handeln
06.03.NextCure Provides Business Update and Reports Full Year 2024 Financial Results104Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million...
► Artikel lesen
03.02.NextCure, Inc. - 8-K, Current Report1
10.01.NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers275BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class...
► Artikel lesen
10.01.NextCure, Inc. - 8-K, Current Report-
10.12.24NextCure Announces Acceptance of IND Application for LNCB744
05.12.24NextCure, Inc. - 8-K, Current Report-
19.11.24NextCure: Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta2
08.11.24NextCure, Inc. - 8-K, Current Report-
08.11.24NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space2
08.11.24NextCure GAAP EPS of -$0.411
07.11.24NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results312Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md....
► Artikel lesen
07.11.24NextCure, Inc. - 10-Q, Quarterly Report-
05.11.24NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting4
04.10.24NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting2
08.04.24NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024160BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1